Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Weak correlations were found between dietary macronutrients and cardiometabolic disease risk markers, with SFA (%TE) intake positively associated with TC, LDL-C, non-HDL-C and NEFA (p ≤ 0.05), whereas carbohydrate (%TE) intake was negatively correlated with LDL-C (p < 0.01).Spearman’s correlation coefficients (rs) for the relationship between DXA body composition measurements, with CVD risk factors and dietary macronutrientsBody fat, %Fat mass, kgLean mass, kgVAT, gAndroid fat, kgAndroid fat %Gynoid fat %A/GBlood pressure, mmHgSystolic−0.030.15**0.33**0.40**0.25**0.14**−0.15**0.33**Diastolic0.13*0.29**0.21**0.44**0.37**0.31**−0.0030.39**Pulse pressure−0.14**−0.020.25**0.16**0.03−0.05−0.19**0.11*BiochemistryTC, mmol/L0.19**0.17**−0.11*0.25**0.23**0.23**0.13*0.20**TAG, mmol/L0.21**0.35**0.18**0.46**0.42**0.38**0.060.43**HDL-C, mmol/L−0.02−0.23**−0.35**−0.35**−0.29**−0.20**0.11*−0.34**LDL-C, mmol/L0.17**0.20**−0.020.32**0.27**0.25**0.090.26**Non-HDL-C, mmol/L0.22**0.27**0.020.41**0.36**0.33**0.100.35**TC: HDL ratio0.18**0.37**0.24**0.55**0.47**0.39**−0.0010.50**LDL-C: HDL-C ratio0.16**0.33**0.23**0.51**0.43**0.35**−0.010.46**NEFA, μmol/L0.20**0.12*−0.17**0.040.10*0.15**0.20**−0.02Glucose, mmol/L0.070.23**0.22**0.41**0.31**0.23**−0.050.35**Insulin, pmol/L0.35**0.41**0.020.34**0.41**0.42**0.24**0.32**HOMA-IR0.34**0.42**0.060.38**0.43**0.42**0.21**0.34**CRP, mg/L0.36**0.41**0.0010.29**0.39**0.41**0.27**0.27**GGT, U/L−0.090.11*0.35**0.37**0.22**0.11−0.22**0.36**Uric acid, µmol/L−0.16**0.13*0.53**0.43**0.29**0.13*−0.35**0.51**Adiponectin, µg/mL0.18**0.02−0.25**−0.14**−0.050.020.25**−0.21Total 25(OH)D, ng/mL−0.16**−0.14**0.05−0.12*−0.08−0.11*−0.15**−0.14**Dietary intakeTotal fat, %TE0.020.01−0.030.010.010.010.020.01SFA %TE0.040.060.010.080.060.040.030.04MUFA, %TE0.01−0.01−0.05−0.02−0.01−0.0040.02−0.01PUFA, %TE−0.07−0.15**−0.09−0.13*−0.16**−0.13*−0.04−0.14**n-6 PUFA, %TE−0.08−0.16**−0.11*−0.17**−0.19**−0.15**−0.02−0.18**n-3 PUFA, %TE−0.004−0.05−0.080.01−0.04−0.010.02−0.03Trans fat, %TE0.070.11*0.070.16**0.13**0.11*0.040.12*Protein, %TE−0.03−0.0030.07−0.04−0.02−0.05−0.03−0.07Carbohydrate, %TE0.020.003−0.05−0.030.0010.020.030.01Fibre (AOAC), g/day−0.22**−0.14**0.21**−0.06−0.13*−0.21**−0.21**−0.07Total Sugars, %TE0.03−0.01−0.11*−0.14**−0.04−0.040.07−0.11*Data analysed by Spearman’s correlationsAOAC association of analytical chemists, A/G android to gynoid ratio, CRP C-reactive protein, GGT gamma-glutamyl transferase, HDL-C high density lipoprotein cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, LDL-C low density lipoprotein cholesterol, MUFA monounsaturated fatty acids, NEFA non-esterified fatty acids, PUFA polyunsaturated fatty acids, SFA saturated fatty acids, TC total cholesterol, TAG triacylglycerol, %TE % of total energy, VAT abdominal visceral adipose tissue, total 25(OH)D: 25-hydroxyvitamin D*Significant differences at the 0.05 level**Significant differences at the 0.01 level

Source: Association between body composition, cardiometabolic disease risk markers and dietary macronutrients. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

For the day prior to this visit, participants were requested to abstain from strenuous exercise and consuming alcohol.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Association between dietary saturated fat with cardiovascular disease risk markers and body composition in healthy adults: findings from the cross-sectional BODYCON study

Study design awaiting verification · Nutrition & Metabolism · 2022

Original publication title

Association between dietary saturated fat with cardiovascular disease risk markers and body composition in healthy adults: findings from the cross-sectional BODYCON study

Ezgi Ozen; Rada Mihaylova; Michelle Weech; Sam Kinsella; Julie A. Lovegrove; Kim G. Jackson

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Although dietary SFA was found to explain 9% of the variability in LDL-C, stratification of data according to quartiles of SFA intake did not reveal a dose-dependent relationship with LDL-C concentration. Furthermore, this association appeared to be independent of abdominal obesity in this cohort.

Clinical Trail registration: Trial registration: clinicaltrials.gov as NCT02658539. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/NCT02658539.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Diets high in saturated fatty acids (SFAs) and greater abdominal obesity are both associated with raised low-density lipoprotein cholesterol (LDL-C) concentrations, an independent cardiovascular disease (CVD) risk marker. Although reducing SFA intake is a public health strategy for CVD prevention, the role of body fat distribution on the relationship between SFA and LDL-C is unclear. Therefore, our objective was to investigate whether the association between dietary SFAs and LDL-C concentrations is related to body composition.

Source: Background

Abstract: What methods does the paper describe?

In the BODYCON (impact of physiological and lifestyle factors on body composition) study, 409 adults [mean age 42 ± 16 years and median BMI of 23.5 (21.5 to 25.9) kg/m2] underwent a measure of body composition by dual energy x-ray absorptiometry, assessment of habitual dietary intake using a 4-day weighed food diary and physical activity level using a tri-axial accelerometer. Blood pressure was measured, and a fasting blood sample was collected to determine cardiometabolic disease risk markers. Correlations between body composition, circulating risk markers and dietary macronutrients were assessed prior to multivariate regression analysis.

The effect of increasing intakes of dietary SFA on outcome measures was assessed using ANCOVA after adjusting for covariates.

Source: Methods

Abstract: Results

Abdominal visceral adipose tissue (VAT) mass was moderately positively correlated with total cholesterol (TC), LDL-C, systolic blood pressure (SBP), diastolic blood pressure and HOMA-IR (rs = 0.25 to 0.44, p < 0.01). In multiple regression analysis, 18.3% of the variability in LDL-C was explained by SFA intake [% total energy (TE)], abdominal VAT mass, carbohydrate%TE and fat%TE intakes. When data were stratified according to increasing SFA%TE intakes, fasting TC, LDL-C and non-high-density lipoprotein-cholesterol were higher in Q4 compared with Q2 (p ≤ 0.03).

SBP was higher in Q4 versus Q3 (p = 0.01). Android lean mass was also higher in Q3 versus Q1 (p = 0.02). Other anthropometric and CVD risk markers were not different across quartile groups.

Source: Results

Abstract: Conclusions

Although dietary SFA was found to explain 9% of the variability in LDL-C, stratification of data according to quartiles of SFA intake did not reveal a dose-dependent relationship with LDL-C concentration. Furthermore, this association appeared to be independent of abdominal obesity in this cohort.

Clinical Trail registration: Trial registration: clinicaltrials.gov as NCT02658539. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/NCT02658539.

Source: Conclusions Source: Conclusions
Authors’ abstract

Background

Diets high in saturated fatty acids (SFAs) and greater abdominal obesity are both associated with raised low-density lipoprotein cholesterol (LDL-C) concentrations, an independent cardiovascular disease (CVD) risk marker. Although reducing SFA intake is a public health strategy for CVD prevention, the role of body fat distribution on the relationship between SFA and LDL-C is unclear. Therefore, our objective was to investigate whether the association between dietary SFAs and LDL-C concentrations is related to body composition.

Methods

In the BODYCON (impact of physiological and lifestyle factors on body composition) study, 409 adults [mean age 42 ± 16 years and median BMI of 23.5 (21.5 to 25.9) kg/m2] underwent a measure of body composition by dual energy x-ray absorptiometry, assessment of habitual dietary intake using a 4-day weighed food diary and physical activity level using a tri-axial accelerometer. Blood pressure was measured, and a fasting blood sample was collected to determine cardiometabolic disease risk markers. Correlations between body composition, circulating risk markers and dietary macronutrients were assessed prior to multivariate regression analysis.

The effect of increasing intakes of dietary SFA on outcome measures was assessed using ANCOVA after adjusting for covariates.

Results

Abdominal visceral adipose tissue (VAT) mass was moderately positively correlated with total cholesterol (TC), LDL-C, systolic blood pressure (SBP), diastolic blood pressure and HOMA-IR (rs = 0.25 to 0.44, p < 0.01). In multiple regression analysis, 18.3% of the variability in LDL-C was explained by SFA intake [% total energy (TE)], abdominal VAT mass, carbohydrate%TE and fat%TE intakes. When data were stratified according to increasing SFA%TE intakes, fasting TC, LDL-C and non-high-density lipoprotein-cholesterol were higher in Q4 compared with Q2 (p ≤ 0.03).

SBP was higher in Q4 versus Q3 (p = 0.01). Android lean mass was also higher in Q3 versus Q1 (p = 0.02). Other anthropometric and CVD risk markers were not different across quartile groups.

Conclusions

Although dietary SFA was found to explain 9% of the variability in LDL-C, stratification of data according to quartiles of SFA intake did not reveal a dose-dependent relationship with LDL-C concentration. Furthermore, this association appeared to be independent of abdominal obesity in this cohort.

Clinical Trail registration: Trial registration: clinicaltrials.gov as NCT02658539. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/NCT02658539.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12986-022-00650-y.

Publication and source details

Original title: Association between dietary saturated fat with cardiovascular disease risk markers and body composition in healthy adults: findings from the cross-sectional BODYCON study

Ezgi Ozen; Rada Mihaylova; Michelle Weech; Sam Kinsella; Julie A. Lovegrove; Kim G. Jackson

Nutrition & Metabolism · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T10:03:04.519202+00:00

DOI: 10.1186/s12986-022-00650-y · PMC8896371